Cardiovascular risk in patients receiving antihypertensive drug treatment from the perspective of endothelial function
- PMID: 35595983
- DOI: 10.1038/s41440-022-00936-x
Cardiovascular risk in patients receiving antihypertensive drug treatment from the perspective of endothelial function
Abstract
Blood-pressure-lowering therapy with antihypertensive drugs can reduce the risk of cardiovascular morbidity and mortality in patients with hypertension. However, patients treated with antihypertensive drugs generally have a worse prognosis than untreated individuals. Consistent with the results obtained from epidemiological studies, a clinical study showed that endothelial function was impaired more in treated patients with hypertension than in untreated individuals with the same blood pressure level, suggesting that blood-pressure-lowering therapy with currently available antihypertensive drugs cannot restore endothelial function to the level of that in untreated individuals. Several mechanisms of endothelial dysfunction in treated patients are postulated: irreversible damage to the endothelium caused by higher cumulative elevated blood pressure exposure over time; the persistence of the primary causes of hypertension even after the initiation of antihypertensive drug treatment, including an activated renin-angiotensin-aldosterone system, oxidative stress, and inflammation; and higher global cardiovascular risk related not only to conventional cardiovascular risk factors but also to undetectable nonconventional risk factors. Lifestyle modifications/nonpharmacological interventions should be strongly recommended for both untreated and treated individuals with hypertension. Lifestyle modifications/nonpharmacological interventions may directly correct the primary causes of hypertension, which can improve endothelial function and consequently reduce cardiovascular risk regardless of the use or nonuse of antihypertensive drugs.
Keywords: Antihypertensive drug treatment; Cardiovascular risk; Endothelium-dependent vasodilation; Flow-mediated vasodilation; Hypertension.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Similar articles
-
Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.Drugs. 2002;62(2):265-84. doi: 10.2165/00003495-200262020-00003. Drugs. 2002. PMID: 11817973 Review.
-
Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan).Hypertension. 2017 Oct;70(4):790-797. doi: 10.1161/HYPERTENSIONAHA.117.09612. Epub 2017 Aug 14. Hypertension. 2017. PMID: 28808069 Clinical Trial.
-
Polyphenol protection and treatment of hypertension.Phytomedicine. 2016 Feb 15;23(2):220-31. doi: 10.1016/j.phymed.2015.12.012. Epub 2016 Jan 7. Phytomedicine. 2016. PMID: 26926184 Review.
-
The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004. Drugs Aging. 2006. PMID: 16536636 Review.
-
Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.Int J Mol Sci. 2019 Jul 14;20(14):3458. doi: 10.3390/ijms20143458. Int J Mol Sci. 2019. PMID: 31337127 Free PMC article. Review.
Cited by
-
The Prevention of the New Onset of Heart Failure in Hypertensive Patients.Intern Med. 2024 Jan 1;63(1):11-15. doi: 10.2169/internalmedicine.0799-22. Epub 2022 Oct 19. Intern Med. 2024. PMID: 36261381 Free PMC article. Review.
-
Preventive effects of SGLT2 inhibitors on incident hypertension in patients with diabetes who do not have hypertension.Hypertens Res. 2024 Jul;47(7):1892-1893. doi: 10.1038/s41440-024-01696-6. Epub 2024 Apr 24. Hypertens Res. 2024. PMID: 38658652 No abstract available.
-
2023 update and perspectives.Hypertens Res. 2024 Jan;47(1):6-32. doi: 10.1038/s41440-023-01398-5. Epub 2023 Sep 15. Hypertens Res. 2024. PMID: 37710033 Review.
-
How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?Hypertens Res. 2024 Mar;47(3):794-795. doi: 10.1038/s41440-023-01542-1. Epub 2023 Dec 19. Hypertens Res. 2024. PMID: 38114652 No abstract available.
-
Relationship between dietary antioxidants and hypertension with the role of genetic factors: a scoping review protocol.Syst Rev. 2025 Jul 19;14(1):151. doi: 10.1186/s13643-025-02913-0. Syst Rev. 2025. PMID: 40684217 Free PMC article.
References
-
- Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical